GPX4 and breast carcinoma: 2020). In addition, upregulation of GSK-3β augmented erastin-induced ferroptosis in breast cancer by upregulating the expression of GPX4, and this augment was blocked by activation of Nrf2, indicating that the GSK-3β/Nrf2 signalling controls ferroptosis by regulating the expression of GPX4 (Wu et al. 2020).